AbbVie Inc. Earnings Per Share Disclosure
| Years ended December 31, | |||||||||||||||||
| (in millions, except per share data) | 2025 | 2024 | 2023 | ||||||||||||||
| Basic EPS | |||||||||||||||||
| Net earnings attributable to AbbVie Inc. | $ | 4,226 | $ | 4,278 | $ | 4,863 | |||||||||||
| Earnings allocated to participating securities | 40 | 40 | 43 | ||||||||||||||
| Earnings available to common shareholders | $ | 4,186 | $ | 4,238 | $ | 4,820 | |||||||||||
| Weighted average basic shares of common stock outstanding | 1,769 | 1,769 | 1,768 | ||||||||||||||
| Basic earnings per share attributable to AbbVie Inc. | $ | 2.37 | $ | 2.40 | $ | 2.73 | |||||||||||
| Diluted EPS | |||||||||||||||||
| Net earnings attributable to AbbVie Inc. | $ | 4,226 | $ | 4,278 | $ | 4,863 | |||||||||||
| Earnings allocated to participating securities | 40 | 40 | 43 | ||||||||||||||
| Earnings available to common shareholders | $ | 4,186 | $ | 4,238 | $ | 4,820 | |||||||||||
| Weighted average shares of common stock outstanding | 1,769 | 1,769 | 1,768 | ||||||||||||||
| Effect of dilutive securities | 4 | 4 | 5 | ||||||||||||||
| Weighted average diluted shares of common stock outstanding | 1,773 | 1,773 | 1,773 | ||||||||||||||
| Diluted earnings per share attributable to AbbVie Inc. | $ | 2.36 | $ | 2.39 | $ | 2.72 | |||||||||||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Feb 20, 2026 | Showing above |
| 2024 | Feb 14, 2025 | |
| 2023 | Feb 20, 2024 | |
| 2022 | Feb 17, 2023 | |
| 2021 | Feb 18, 2022 | |
| 2020 | Feb 19, 2021 | |
| 2019 | Feb 21, 2020 | |
| 2018 | Feb 27, 2019 | |
| 2017 | Feb 16, 2018 | |
| 2016 | Feb 17, 2017 | |
| 2015 | Feb 19, 2016 | |
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.